Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP066
MIFTS: 64

Hyperglycemia

Categories: Blood diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hyperglycemia

About this section

MalaCards integrated aliases for Hyperglycemia:

Name: Hyperglycemia 12 77 30 56 6 44 45 15 74

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:4195
MeSH 45 D006943
NCIt 51 C26797
SNOMED-CT 69 80394007
ICD10 34 R73.9
UMLS 74 C0020456
Sources

Summaries for Hyperglycemia

About this section
MedlinePlus : 44 Hyperglycemia means high blood sugar or glucose. Glucose comes from the foods you eat. Insulin is a hormone that moves glucose into your cells to give them energy. Hyperglycemia happens when your body doesn't make enough insulin or can't use it the right way. People with diabetes can get hyperglycemia from not eating the right foods or not taking medicines correctly. Other problems that can raise blood sugar include infections, certain medicines, hormone imbalances, or severe illnesses.

MalaCards based summary : Hyperglycemia is related to diabetes mellitus, transient neonatal, 1 and maturity-onset diabetes of the young, type 2, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hyperglycemia is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Developmental Biology and Aldosterone synthesis and secretion. The drugs Zinc and Glipizide have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and brain, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 77 Hyperglycemia (also spelled hyperglycaemia or hyperglycæmia), is a condition in which an excessive... more...

Sources

Related Diseases for Hyperglycemia

About this section

Diseases related to Hyperglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 471)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, transient neonatal, 1 32.8 ABCC8 INS KCNJ11
2 maturity-onset diabetes of the young, type 2 32.8 GCK HNF1A INS PDX1
3 diabetes mellitus, permanent neonatal 32.3 ABCC8 GCK INS KCNJ11 PDX1
4 diabetes mellitus, insulin-dependent 32.0 AKR1B1 ALB GCG GCK HNF1A IAPP
5 hyperinsulinism 32.0 ABCC8 GCK IGF1 INS INSR KCNJ11
6 microvascular complications of diabetes 1 31.9 AKR1B1 IGF1 INS SST
7 hypoglycemia 31.2 ABCC8 GCG GCK INS INSR KCNJ11
8 lipid metabolism disorder 31.0 ADIPOQ INS LEP PPARG
9 microvascular complications of diabetes 5 30.8 AKR1B1 ALB IGF1 INS
10 fatty liver disease, nonalcoholic 1 30.7 ADIPOQ INS LEP
11 microvascular complications of diabetes 3 30.7 ALB INS MALAT1
12 acromegaly 30.5 IGF1 INS SST
13 gestational diabetes 30.4 ADIPOQ GCK IAPP INS INSR KCNJ11
14 vascular disease 30.4 ADIPOQ ALB INS PPARG
15 diabetic neuropathy 30.4 AKR1B1 INS LEP
16 atherosclerosis susceptibility 30.3 ADIPOQ INS PPARG
17 arteries, anomalies of 30.3 ADIPOQ ALB INS LEP PPARG
18 liver disease 30.2 ADIPOQ ALB INS LEP
19 nonalcoholic fatty liver disease 30.2 ADIPOQ INS LEP
20 fanconi-bickel syndrome 30.2 ABCC8 INS SLC2A2
21 polycystic ovary syndrome 30.2 IGF1 INS INSR LEP
22 chronic kidney failure 30.2 ADIPOQ ALB IGF1 INS LEP
23 glucose intolerance 30.2 ADIPOQ DPP4 GCG GCK IGF1 INS
24 insulin-like growth factor i 30.1 IGF1 INS INSR LEP SST
25 sleep apnea 30.1 ADIPOQ IGF1 INS LEP
26 peripheral nervous system disease 30.0 AKR1B1 ALB INS
27 islet cell tumor 30.0 IAPP INS SST
28 retinal vascular disease 30.0 AKR1B1 ALB INS
29 hyperandrogenism 30.0 IGF1 INS INSR
30 fatty liver disease 30.0 ADIPOQ INS INSR LEP MALAT1
31 uremia 29.9 ALB INS LEP
32 monogenic diabetes 29.7 ABCC8 GCK HNF1A INS KCNJ11 PDX1
33 abdominal obesity-metabolic syndrome 1 29.7 ADIPOQ INS LEP PPARG
34 hyperthyroidism 29.7 INS LEP SST
35 insulinoma 29.6 ABCC8 GCG GCK IAPP INS PDX1
36 maturity-onset diabetes of the young 29.6 ABCC8 DPP4 GCG GCK HNF1A IAPP
37 neonatal diabetes mellitus 29.6 ABCC8 GCK INS KCNJ11 PDX1 SLC2A2
38 hypertension, essential 29.5 ADIPOQ ALB INS INSR LEP
39 prediabetes syndrome 29.5 ADIPOQ ALB DPP4 GCG INS LEP
40 body mass index quantitative trait locus 11 29.3 ADIPOQ DPP4 GCG GCK IAPP IGF1
41 anorexia nervosa 29.1 ADIPOQ IGF1 LEP
42 diabetes mellitus 28.9 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCG
43 diabetes mellitus, noninsulin-dependent 28.9 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCG
44 mitochondrial complex iii deficiency, nuclear type 6 11.5
45 diabetes mellitus, ketosis-prone 11.4
46 diabetes and deafness, maternally inherited 11.4
47 transient neonatal diabetes mellitus 11.4
48 diabetes mellitus, insulin-dependent, 2 11.2
49 brittle diabetes 11.2
50 pancreas, dorsal, agenesis of 11.1

Graphical network of the top 20 diseases related to Hyperglycemia:



Diseases related to Hyperglycemia
Sources

Symptoms & Phenotypes for Hyperglycemia

About this section

UMLS symptoms related to Hyperglycemia:


seizures, fever, dyspnea, edema, cachexia, vertigo, headache, syncope, cyanosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, symptoms

MGI Mouse Phenotypes related to Hyperglycemia:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCK
2 growth/size/body region MP:0005378 10.36 ADIPOQ AKR1B1 DPP4 GCK HNF1A IAPP
3 endocrine/exocrine gland MP:0005379 10.32 ABCC8 ADIPOQ ALB DPP4 GCK HNF1A
4 behavior/neurological MP:0005386 10.25 ADIPOQ AKR1B1 HNF1A INS INSR KCNJ11
5 adipose tissue MP:0005375 10.18 ADIPOQ HNF1A IGF1 INS INSR KCNJ11
6 mortality/aging MP:0010768 10.17 ADIPOQ AKR1B1 ALB GCK HNF1A IGF1
7 digestive/alimentary MP:0005381 10.1 ALB HNF1A INS INSR LEP PDX1
8 liver/biliary system MP:0005370 10.07 ADIPOQ ALB GCK HNF1A INS INSR
9 integument MP:0010771 10.01 ADIPOQ HNF1A IGF1 INS KCNJ11 LEP
10 muscle MP:0005369 10 ADIPOQ ALB HNF1A IGF1 INS INSR
11 renal/urinary system MP:0005367 9.73 ADIPOQ AKR1B1 ALB GCK HNF1A IGF1
12 no phenotypic analysis MP:0003012 9.7 ABCC8 HNF1A INS KCNJ11 PDX1 PPARG
13 skeleton MP:0005390 9.32 ADIPOQ AKR1B1 HNF1A IAPP IGF1 INS
Sources

Drugs & Therapeutics for Hyperglycemia

About this section

Drugs for Hyperglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 867)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051
2
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2 29094-61-9 3478
3
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Not Applicable 361442-04-8 11243969
4
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
5
Insulin glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
6
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
7
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 62-31-7, 51-61-6 681
8
Insulin glulisine Approved Phase 4,Phase 3,Phase 2,Not Applicable 207748-29-6
9
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Not Applicable 169148-63-4 5311023
10
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56180-94-0 441184
11
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
12
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 116094-23-6 16132418
13
Curcumin Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 458-37-7 969516
14
Celecoxib Approved, Investigational Phase 4,Phase 1,Phase 2 169590-42-5 2662
15
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
16
Parecoxib Approved Phase 4 198470-84-7
17
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
18
Nitric Oxide Approved Phase 4,Phase 2,Not Applicable 10102-43-9 145068
19
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
20
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
21
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
22
Amlodipine Approved Phase 4 88150-42-9 2162
23
Clonidine Approved Phase 4 4205-90-7 2803
24
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2 58-93-5 3639
25
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
26
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
27
Atenolol Approved Phase 4 29122-68-7 2249
28
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
29
Doxazosin Approved Phase 4 74191-85-8 3157
30
Furosemide Approved, Vet_approved Phase 4,Phase 2 54-31-9 3440
31
Valsartan Approved, Investigational Phase 4,Phase 1,Phase 2 137862-53-4 60846
32
Glucagon Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16941-32-5
33
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-23-7 5754
34
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-03-3
35
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
36
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
37
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
38
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
39
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
40
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 122320-73-4 77999
41
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
42
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
43
Insulin Lispro Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 133107-64-9
44
Liraglutide Approved Phase 4,Phase 3,Phase 2,Not Applicable 204656-20-2 44147092
45
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
48
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 98-92-0 936
49
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
50
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838

Interventional clinical trials:

(show top 50) (show all 2203)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effects of Insulin and Berberine on Stress Hyperglycemia Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
2 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
3 Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
4 Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes (FIT) Unknown status NCT03057470 Phase 4 50% bolus insulin correction;100% bolus insulin correction;150% bolus insulin correction
5 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
6 ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia Unknown status NCT01717911 Phase 4 Insulin;Metformin;Sitagliptin
7 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
8 Arterial Catheter to Monitor Glycemia Unknown status NCT01176279 Phase 4
9 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
10 A Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU Unknown status NCT02491346 Phase 4
11 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
12 The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients Unknown status NCT01270191 Phase 4 Exenatide;Humulin-N
13 Insulin Infusion Diabetes Ulcer Unknown status NCT00700154 Phase 4
14 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
15 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
16 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
17 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
18 Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
19 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
20 Exenatide and Brown Adipose Tissue Unknown status NCT03002675 Phase 4 Bydureon
21 Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes. Unknown status NCT00254085 Phase 4 Insulin Aspart
22 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
23 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
24 Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
25 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
26 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
27 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
28 TReatment by Insulin Continuous Infusion in Type 2 DIAbetes Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
29 Comparison Study of Insulin Glargine and NPH Insulin Unknown status NCT01854723 Phase 4 Switching to NPH insulin;Continuation of insulin glargine
30 Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
31 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
32 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
33 Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
34 Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy Unknown status NCT03112538 Phase 4 Multiple daily injections of insulin
35 Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
36 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
37 Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery Completed NCT02556918 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
38 Hyperglycemia and Effects of Daily 100 mg Versus 200 mg of Hydrocortisone Therapy in Patients With Septic Shock Completed NCT02266264 Phase 4 Hydrocortisone
39 Sitagliptin in Non-Diabetic Patients Undergoing General Surgery Completed NCT02741687 Phase 4 Sitagliptin;Placebo;Supplemental insulin (insulin lispro);Supplemental insulin (insulin aspart);Long acting basal insulin (insulin detemir);Long acting basal insulin (insulin glargine)
40 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy
41 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia Completed NCT01184014 Phase 4 NPH insulin plus Complete Insulin Orders;Complete Insulin Orders
42 Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery Completed NCT02443402 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
43 NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens Completed NCT02758522 Phase 4 Once-daily Insulin;Twice-daily Insulin;Triple-daily Insulin
44 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Completed NCT01810952 Phase 4 Glargine insulin;Lispro insulin;NPH Insulin
45 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
46 Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia Completed NCT00362778 Phase 4 Insulin
47 Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery Completed NCT01545700 Phase 4 Control-saline;Dexamethasone 4 mg;Dexamethasone 8 mg;Control saline;Dexamethasone 4 mg;Dexamethasone 8 mg
48 Study of a Model-based Approach to Blood Glucose Control in Very-low-birthweight Neonates Completed NCT01419873 Phase 4 Actrapid Human Insulin
49 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes Completed NCT00191282 Phase 4 Insulin lispro;Human insulin isophane suspension (NPH);Insulin glargine;Human insulin isophane suspension;Human insulin 30/70
50 A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes Completed NCT01159938 Phase 4 Lispro

Search NIH Clinical Center for Hyperglycemia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hyperglycemia

Sources

Genetic Tests for Hyperglycemia

About this section

Genetic tests related to Hyperglycemia:

# Genetic test Affiliating Genes
1 Hyperglycemia 30
Sources

Anatomical Context for Hyperglycemia

About this section

MalaCards organs/tissues related to Hyperglycemia:

42
Endothelial, Heart, Brain, Liver, Pancreas, Kidney, Testes
Sources

Publications for Hyperglycemia

About this section

Articles related to Hyperglycemia:

(show top 50) (show all 3847)
# Title Authors Year
1
Feasibility and safety of using an automated decision support system for insulin therapy in the treatment of steroid-induced hyperglycemia in patients with acute graft-versus-host disease: A randomized trial. ( 30144380 )
2019
2
Aging and Hyperglycemia Intensify Dyslipidemia-Induced Oxidative Stress and Inflammation in Rats: Assessment of Restorative Potentials of ALA and EPA + DHA. ( 30535619 )
2019
3
Regarding "Outcomes associated with hyperglycemia after abdominal aortic aneurysm repair". ( 30579453 )
2019
4
Outcomes associated with hyperglycemia after abdominal aortic aneurysm repair. ( 30154015 )
2019
5
Decreased numbers of circulating endothelial progenitor cells are associated with hyperglycemia in patients with traumatic brain injury. ( 30762009 )
2019
6
Incretin dysfunction and hyperglycemia in cystic fibrosis: Role of acyl-ghrelin. ( 30738804 )
2019
7
Association of hyperglycemia episodes on long-term mortality in type 2 diabetes mellitus with vascular dementia: A population-based cohort study. ( 30420126 )
2019
8
Hyperglycemia recognised in early pregnancy is phenotypically type 2 diabetes mellitus not gestational diabetes mellitus: a case control study. ( 30913941 )
2019
9
Hyperglycemia inhibition of endothelial miR-140-3p mediates angiogenic dysfunction in diabetes mellitus. ( 30862410 )
2019
10
Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Gestational Diabetes Mellitus and Childhood Glucose Metabolism. ( 30655380 )
2019
11
Downregulation of peroxisome proliferator-activated receptor gamma in the placenta correlates to hyperglycemia in offspring at young adulthood after exposure to gestational diabetes mellitus. ( 30187673 )
2019
12
Hyperglycemia-Driven Neuroinflammation Compromises BBB Leading to Memory Loss in Both Diabetes Mellitus (DM) Type 1 and Type 2 Mouse Models. ( 29974394 )
2019
13
Hyperglycemia and Glucose Variability Are Associated with Worse Brain Function and Seizures in Neonatal Encephalopathy: A Prospective Cohort Study. ( 30982528 )
2019
14
What Constitutes Ideal Perioperative Glycemic Control for Preventing Acute Postoperative Hyperglycemia in Surgical Patients with Nonalcoholic Fatty Liver Disease? ( 30685022 )
2019
15
The effects of hyperglycemia on outcomes in surgical high-grade glioma patients. ( 30784896 )
2019
16
Hyperglycemia-induced oxidative brain injury: Therapeutic effects of Cola nitida infusion against redox imbalance, cerebellar neuronal insults, and upregulated Nrf2 expression in type 2 diabetes rats. ( 30914353 )
2019
17
Methanol-Extract/Fractions of Dacryodes edulis Leaves Ameliorate Hyperglycemia and Associated Oxidative Stress in Streptozotocin-Induced Diabetic Wistar Rats. ( 31055945 )
2019
18
Searching for mutations in the HNF1B gene in a Brazilian cohort with renal cysts and hyperglycemia. ( 31066763 )
2019
19
Enterococcus faecalis YM0831 suppresses sucrose-induced hyperglycemia in a silkworm model and in humans. ( 31069266 )
2019
20
CHANGING TO BASAL-BOLUS INSULIN THERAPY FOR THE INPATIENT MANAGEMENT OF HYPERGLYCEMIA-A NATURAL EXPERIMENT. ( 31070947 )
2019
21
Interleukin 6 Function in the Skin and Isolated Keratinocytes Is Modulated by Hyperglycemia. ( 31073533 )
2019
22
Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The MUSCLES-DM study. ( 31074209 )
2019
23
Diagnostic thresholds for pregnancy hyperglycemia, maternal weight status and the risk of childhood obesity in a diverse Northern California cohort using health care delivery system data. ( 31075132 )
2019
24
Toll-like receptor 4 (TLR4) as a possible pathological mechanism in hyperglycemia-associated testicular dysfunction. ( 31088634 )
2019
25
Hyperglycemia Enhances Constriction of Retinal Venules via Activation of the Reverse-Mode Sodium-Calcium Exchanger. ( 31088854 )
2019
26
Extract of ice plant (Mesembryanthemum crystallinum) ameliorates hyperglycemia and modulates the gut microbiota composition in type 2 diabetic Goto-Kakizaki rats. ( 31089648 )
2019
27
Role of tea polyphenols in delaying hyperglycemia-induced senescence in human glomerular mesangial cells via miR-126/Akt-p53-p21 pathways. ( 31089945 )
2019
28
Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison to GCK-MODY (MODY2). ( 31092478 )
2019
29
A Protective Role of Paeoniflorin in Fluctuant Hyperglycemia-Induced Vascular Endothelial Injuries through Antioxidative and Anti-Inflammatory Effects and Reduction of PKCβ1. ( 31093316 )
2019
30
STAT3 dictates β-cell apoptosis by modulating PTEN in streptozocin-induced hyperglycemia. ( 31097787 )
2019
31
Green Tea Ameliorates Hyperglycemia by Promoting the Translocation of Glucose Transporter 4 in the Skeletal Muscle of Diabetic Rodents. ( 31100973 )
2019
32
Hyperglycemia and Carotenoid Intake Are Associated with Serum Carotenoids in Youth with Type 1 Diabetes. ( 31101482 )
2019
33
Response to: Relation between cortisol and admission blood glucose in patients admitted with myocardial infarction but without hyperglycemia! ( 31103289 )
2019
34
Fermented Momordica charantia L. juice modulates hyperglycemia, lipid profile, and gut microbiota in type 2 diabetic rats. ( 31108759 )
2019
35
Glucose regulation by modified boronic acid-sulfobetaine zwitterionic nanogels - a non-hormonal strategy for the potential treatment of hyperglycemia. ( 31112182 )
2019
36
Stress hyperglycemia: A prospective study examining the relationship between glucose, cortisol and diabetes in myocardial infarction. ( 30691725 )
2019
37
Preoperative Protein or Methionine Restriction Preserves Wound Healing and Reduces Hyperglycemia. ( 30691797 )
2019
38
Assessing quality of glycemic control: Hypo- and hyperglycemia, and glycemic variability using mobile self-monitoring of blood glucose system. ( 30693833 )
2019
39
Obesity and inactivity, not hyperglycemia, cause exercise intolerance in individuals with type 2 diabetes: Solving the obesity and inactivity versus hyperglycemia causality dilemma. ( 30696579 )
2019
40
Hyperglycemia and Risk of All-cause Mortality Among People Living With HIV With and Without Tuberculosis Disease in Myanmar (2011-2017). ( 30697575 )
2019
41
Lean maternal hyperglycemia alters offspring lipid metabolism and susceptibility to diet-induced obesity in mice†. ( 30698664 )
2019
42
Glucose Activates Vagal Control of Hyperglycemia and Inflammation in Fasted Mice. ( 30700738 )
2019
43
An insoluble polysaccharide from the sclerotium of Poria cocos improves hyperglycemia, hyperlipidemia and hepatic steatosis in ob/ob mice via modulation of gut microbiota. ( 30704621 )
2019
44
Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy. ( 30717892 )
2019
45
Acute Hyperglycemia Due to Topical Corticosteroid Administration. ( 30719358 )
2019
46
Chronic insulinopenia/hyperglycemia decrease cannabinoid CB1 receptor density and impair glucose uptake in the mouse forebrain. ( 30721768 )
2019
47
Acute effects of hyperglycemia on the peripheral nervous system in zebrafish ( Danio rerio) following nitroreductase-mediated β-cell ablation. ( 30726116 )
2019
48
Intestinal electrical stimulation attenuates hyperglycemia and prevents loss of pancreatic β cells in type 2 diabetic Goto-Kakizaki rats. ( 30728346 )
2019
49
Evaluation of the Impact of an Inpatient Hyperglycemia Protocol on Glycemic Control. ( 30730832 )
2019
50
Severe Uncontrolled Maternal Hyperglycemia Induces Microsomia and Neurodevelopment Delay Accompanied by Apoptosis, Cellular Survival, and Neuroinflammatory Deregulation in Rat Offspring Hippocampus. ( 30739252 )
2019
Sources

Variations for Hyperglycemia

About this section

ClinVar genetic disease variations for Hyperglycemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KLF11 NM_003597.4(KLF11): c.23G> A (p.Gly8Asp) single nucleotide variant Uncertain significance rs1553312826 GRCh37 Chromosome 2, 10183866: 10183866
2 KLF11 NM_003597.4(KLF11): c.23G> A (p.Gly8Asp) single nucleotide variant Uncertain significance rs1553312826 GRCh38 Chromosome 2, 10043739: 10043739

Copy number variations for Hyperglycemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 44162 10 52900000 70600000 Copy number TFAM Hyperglycemia
Sources

Expression for Hyperglycemia

About this section
Search GEO for disease gene expression data for Hyperglycemia.
Sources

Pathways for Hyperglycemia

About this section

Pathways related to Hyperglycemia according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Developmental Biology 67
Show member pathways
 13.41 ADIPOQ GCK HNF1A IAPP INS LEP
2
Aldosterone synthesis and secretion 38
Show member pathways
 12.87 ABCC8 ALB GCG GCK INS KCNJ11
3
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.37 ADIPOQ IGF1 INS INSR LEP PPARG
4
Prolactin Signaling Pathway 1 38
Show member pathways
 12.35 GCK INS LEP SLC2A2
5
Integration of energy metabolism 67
Show member pathways
 12.3 ABCC8 ADIPOQ GCG INS KCNJ11 SLC2A2
6
Glucose / Energy Metabolism 4
12.25 ADIPOQ GCG HNF1A INS INSR PDX1
7
Peptide hormone metabolism 67
Show member pathways
 12.18 DPP4 GCG IGF1 INS LEP
8
Longevity regulating pathway 38
Show member pathways
 12.09 ADIPOQ IGF1 INS INSR PPARG
9
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
12.02 ALB IGF1 INS PDX1 SLC2A2
10
Adipogenesis 1
11.97 ADIPOQ HNF1A IGF1 INS LEP PPARG
11
Hepatic ABC Transporters 65
Show member pathways
 11.89 GCK HNF1A INS INSR PDX1 SLC2A2
12
Insulin resistance 38
Show member pathways
 11.85 INS INSR SLC2A2
13
Glucagon signaling pathway 38
11.81 GCG GCK SLC2A2
14
Hexose transport 67
Show member pathways
 11.79 GCK SLC2A2 SLC5A2
15
HIF-1 signaling pathway 38
11.78 IGF1 INS INSR
16
Regulation of beta-cell development 67
Show member pathways
 11.73 GCK HNF1A IAPP INS PDX1 SLC2A2
17
Type II diabetes mellitus 1 38
Show member pathways
 11.59